A number of research firms have changed their ratings and price targets for BioCryst Pharmaceuticals (NASDAQ: BCRX):

  • 9/14/2017 – BioCryst Pharmaceuticals is now covered by analysts at Royal Bank Of Canada. They set a “sector perform” rating on the stock.
  • 9/6/2017 – BioCryst Pharmaceuticals had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
  • 9/6/2017 – BioCryst Pharmaceuticals was upgraded by analysts at Jefferies Group LLC from a “hold” rating to a “buy” rating. They now have a $7.00 price target on the stock, up previously from $5.00.
  • 9/6/2017 – BioCryst Pharmaceuticals had its price target raised by analysts at J P Morgan Chase & Co from $4.93 to $9.00. They now have a “neutral” rating on the stock.
  • 9/5/2017 – BioCryst Pharmaceuticals had its “overweight” rating reaffirmed by analysts at Piper Jaffray Companies. They now have a $15.00 price target on the stock, up previously from $13.00.
  • 9/5/2017 – BioCryst Pharmaceuticals was upgraded by analysts at J P Morgan Chase & Co from a “neutral” rating to an “overweight” rating. They now have a $9.00 price target on the stock, up previously from $6.00.
  • 9/3/2017 – BioCryst Pharmaceuticals was downgraded by analysts at ValuEngine from a “hold” rating to a “sell” rating.
  • 8/28/2017 – BioCryst Pharmaceuticals was upgraded by analysts at ValuEngine from a “sell” rating to a “hold” rating.
  • 8/25/2017 – BioCryst Pharmaceuticals was upgraded by analysts at BidaskClub from a “strong sell” rating to a “sell” rating.
  • 8/18/2017 – BioCryst Pharmaceuticals was downgraded by analysts at BidaskClub from a “sell” rating to a “strong sell” rating.
  • 8/10/2017 – BioCryst Pharmaceuticals was downgraded by analysts at ValuEngine from a “hold” rating to a “sell” rating.
  • 8/10/2017 – BioCryst Pharmaceuticals was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “BioCryst Pharmaceuticals, Inc. is a leader in the use of crystallography and structure-based drug design for the development of novel therapeutics to treat cancer, cardiovascular diseases, autoimmune diseases, and viral infections. The company is advancing multiple internal programs toward potential commercialization including Fodosine in oncology, BCX-4208 in transplantation and autoimmune diseases and peramivir in seasonal and life threatening influenza. BioCryst has a worldwide partnership with Roche for the development and commercialization BCX-4208, and is collaborating with Mundipharma for the development and commercialization of Fodosine in markets across Europe, Asia, Australia and certain neighboring countries. “
  • 8/9/2017 – BioCryst Pharmaceuticals was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $5.00 price target on the stock. According to Zacks, “BioCryst Pharmaceuticals, Inc. is a leader in the use of crystallography and structure-based drug design for the development of novel therapeutics to treat cancer, cardiovascular diseases, autoimmune diseases, and viral infections. The company is advancing multiple internal programs toward potential commercialization including Fodosine in oncology, BCX-4208 in transplantation and autoimmune diseases and peramivir in seasonal and life threatening influenza. BioCryst has a worldwide partnership with Roche for the development and commercialization BCX-4208, and is collaborating with Mundipharma for the development and commercialization of Fodosine in markets across Europe, Asia, Australia and certain neighboring countries. “
  • 8/8/2017 – BioCryst Pharmaceuticals had its “buy” rating reaffirmed by analysts at HC Wainwright.
  • 8/8/2017 – BioCryst Pharmaceuticals had its “buy” rating reaffirmed by analysts at Noble Financial.
  • 8/1/2017 – BioCryst Pharmaceuticals was upgraded by analysts at BidaskClub from a “strong sell” rating to a “sell” rating.

Shares of BioCryst Pharmaceuticals, Inc. (BCRX) opened at 5.16 on Friday. The company’s market cap is $415.01 million. BioCryst Pharmaceuticals, Inc. has a 52 week low of $3.75 and a 52 week high of $9.25. The firm’s 50-day moving average price is $4.86 and its 200 day moving average price is $6.09.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its quarterly earnings data on Monday, August 7th. The biotechnology company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.02). BioCryst Pharmaceuticals had a negative net margin of 160.97% and a negative return on equity of 276.62%. The company had revenue of $3.10 million during the quarter, compared to the consensus estimate of $5.79 million. During the same quarter in the prior year, the company posted ($0.22) earnings per share. The company’s revenue for the quarter was down 35.4% on a year-over-year basis. On average, equities analysts predict that BioCryst Pharmaceuticals, Inc. will post ($0.75) EPS for the current fiscal year.

BioCryst Pharmaceuticals, Inc is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. It uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology.

Receive News & Ratings for BioCryst Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.